secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001639691-25-000099
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LivaNova Q2 revenue $352.5M (+10.7%), raises FY25 adjusted EPS guidance to $3.70-$3.80
--------------------------------------------------------------------------------

- Revenue $352.5M, +10.7% reported, +10.3% organic; GAAP EPS $0.50, adjusted EPS $1.05.
- Raised FY25 guidance: revenue growth 8-9% constant-currency, adj. EPS $3.70-$3.80 (midpoint +$0.10).
- Adj. free cash flow $47.8M; FY25 raised to $140-160M.
- Initiated CMS reconsideration for VNS Therapy for treatment-resistant depression based on RECOVER study.
- Published 24-month CORE-VNS data showing VNS reduces generalized tonic-clonic seizures in DRE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969125000099/0001639691-25-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969125000099/livn-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001639691-25-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer